Cullinan Therapeutics (CGEM) Equity Ratio: 2020-2023
Historic Equity Ratio for Cullinan Therapeutics (CGEM) over the last 3 years, with Sep 2023 value amounting to 0.95.
- Cullinan Therapeutics' Equity Ratio fell 0.20% to 0.95 in Q3 2023 from the same period last year, while for Sep 2023 it was 0.95, marking a year-over-year decrease of 0.20%. This contributed to the annual value of 0.95 for FY2022, which is 2.00% down from last year.
- Cullinan Therapeutics' Equity Ratio amounted to 0.95 in Q3 2023, which was down 0.98% from 0.96 recorded in Q2 2023.
- In the past 5 years, Cullinan Therapeutics' Equity Ratio ranged from a high of 0.99 in Q2 2021 and a low of 0.91 during Q2 2022.
- Over the past 3 years, Cullinan Therapeutics' median Equity Ratio value was 0.96 (recorded in 2023), while the average stood at 0.96.
- Its Equity Ratio has fluctuated over the past 5 years, first fell by 8.24% in 2022, then grew by 5.62% in 2023.
- Quarterly analysis of 4 years shows Cullinan Therapeutics' Equity Ratio stood at 0.93 in 2020, then increased by 4.29% to 0.97 in 2021, then decreased by 2.00% to 0.95 in 2022, then dropped by 0.20% to 0.95 in 2023.
- Its Equity Ratio stands at 0.95 for Q3 2023, versus 0.96 for Q2 2023 and 0.94 for Q1 2023.